Showing posts with label Retina. Show all posts
Showing posts with label Retina. Show all posts

Tuesday, August 10, 2010

Green laser pointer can cause eye damage

astronomy: green laser pointing Orion (animation)Image via Wikipedia

Green laser pointers are readily available in stores and on the Internet. Class 3A green laser pointers are increasingly being used by amateur astronomers to pinpoint objects in the night sky and by the construction industry and architecture educators to point out details of structures in daylight.

Dennis Robertson, M.D., Mayo Clinic ophthalmologist, conducted investigations with a green laser pointer directed to the retina of a patient’s eye - scheduled for removal because of a malignancy.
The exposure was 60 seconds to the fovea, the center of acute vision; five minutes to a site 5 degrees below the fovea; and 15 minutes to a site 5 degrees above the fovea. Color photographs were taken of the eye before and after exposure to the laser.

The green laser damaged the pigment layer of the retina, although it did not cause a measurable decrease in the visual function of the patient’s eye. it is believed that longer exposures could harm vision.
Enhanced by Zemanta

Monday, August 02, 2010

Artificial Retina with Micro Fabrication


An implantable artificial retina fabricated at Lawrence Livermore National Laboratory is bringing sight to the blind.

“We’re talking about our progress and where we see the project going,” said Sat Pannu, who leads Livermore’s Center for Micro- and Nano-Technology, which has developed the microfabrication technology.

The project has many partners — including Second Sight Medical Products Inc., the Southern California company that has licensed the technology. Early, lower-resolution versions of the device allow people blinded for decades by the genetic eye disease Retinitis Pigmentosa or by age-related macular degeneration to see images, albeit fuzzy.

This is how it works: A miniature camera, which sits inside a pair of sunglasses, sends images wirelessly to a microprocessor worn on a patient’s belt. There it is converted to an electronic signal that is sent to a receiver on the eye, which sends the signal via a thin cable to a nanofabricated, watch-battery-size microelectrode array that is surgically tacked onto the retina. The array then emits pulses to the optic nerve, which sends a signal to the brain for processing.
The camera allows patients to zoom in and adjust the contrast of an image, Pannu said.

The project is led by Mark Humayun, a surgeon with a doctorate in biomedical engineering, at the Doheny Eye Institute at the University of Southern California. The lead laboratory is Oak Ridge National Lab in Tennessee.

Pannu, who has worked on the project since 2003, is turning again to the Department of Energy as well as the National Institutes of Health for the cash it would take to continue development through the highest-resolution version.


Enhanced by Zemanta

Sunday, August 01, 2010

Tribal Clinic Working On Telemedecine

Low-resolution image of the Oregoh Health and ...Image via Wikipedia

Yellowhawk Tribal Health Center near Pendleton, OR, is one of two tribal clinics (the other is in Wichita, Kan.) working on a test of long-distance eye care with researchers from Oregon Health & Science University and Legacy Health's Devers Eye Institute. This effort waqs highlighted by The Oregonian

At Yellowhawk, patients with diabetes can undergo a retinal scan with a $20,000-plus non-mydriatic camera, which can photograph the retina without dilating the pupil. Next, the images are uploaded to the Internet and sent to doctors in Portland who check for signs of retinopathy. The images also allow doctors to check for glaucoma or macular degeneration.
Enhanced by Zemanta

Wednesday, July 28, 2010

Eye-Related Problems Linked To Diet, Sun, And Smoking

http://www.nei.nih.gov/health/maculardegen/arm...Image via Wikipedia

A diet rich in all the things that are known to be good for your health also can protect against vision-stealing cataracts, according to a study in the Archives of Ophthalmology.

In a survey of more than 1,800 women, those whose diets were poor in fruits, vegetables and whole grains had a high risk of developing cataracts - deposits of altered proteins in the lens of the eye that can impair vision, according to Julie Mares, an ophthalmology professor at UW and lead author of the study

Separately, a preliminary study in the same journal found a correlation between high levels of sun exposure combined with the taking of certain medicines, including antibiotics and anti-depressants, with cataract formation.
Another study in the same journal shows a link between smoking and the development of one of the leading causes of blindness, age-related macular degeneration. Researchers aren't sure why smoking is linked with macular degeneration. Hypotheses include the suppression of antioxidants by tobacco smoke and impairment of blood circulation in the eye, said the report's lead author, Ronald Klein, an ophthalmology and visual sciences professor.

The findings on macular degeneration involved 2,800 people and come from the Beaver Dam Offspring Study. It is a second massive study of vision and eye diseases that the Kleins have conducted. The first, known as the Beaver Dam Eye Study, or BDES, began in 1987 and is ongoing. The offspring research involves the sons and daughters of participants in the first eye study.
Enhanced by Zemanta

Friday, July 09, 2010

FDA Approves Implantable Telescope To Help Patients With AMD



FDA has approved a first-of-its-kind technology to counter a leading cause of blindness in older adults -- a tiny telescope implanted inside the eye.
The Implantable Miniature Telescope aims to help in the end stages of incurable age-related macular degeneration, although the FDA warned Tuesday that patients need post-surgery rehabilitation to make it work.

Dr. Malvina Eydelman, FDA's ophthalmic devices chief, said the device can improve the quality of life for those who are 75 and older, have a certain degree of vision loss and who also need a cataract removed. In addition, the FDA took the highly unusual step of requiring that patients and their surgeons sign a detailed 'acceptance of risk agreement' before surgery, acknowledging potential side effects -- including corneal damage and worsened vision -- and the need for lots of testing to determine who's a candidate.

The benefits of the telescopic implants are numerous, such as:

1. Improving the central vision acuity of patients.

2. Can be used in combination with drugs to treat macular degeneration and photodynamic thepray. The use of anti-hypertensive and anti-angiogenic drugs to treat wet advanced macular degeneration, a condition in which ocular arteries leak inside the eye, include ranibizumab and bevabizumab which can cost upto $2,000 per treatment. Ideally, these prosthetic implants will be offered to patients who have undergone photodynamic therapy to destroy "leaky" blood vessels of the eye before this implant can be made in one eye.

3. It may be more cost effective to use these telescopic implants for the treatment of both dry and wet age related macular degeneration over time compared to the continual, protracted and expensive use of drugs. With time, the dosage and use of these drugs can be reduced once the damaged tissue is healed and the implant has been placed in one of the affected eyes.

"The telescope implant represents a new category of treatment for this severely visually impaired population," said Allen W. Hill, CEO of VisionCare.



Enhanced by Zemanta

Friday, June 04, 2010

Model of a human eye. Features mentioned in th...Image via Wikipedia

MIT's Technology Review reports that researchers from the University of California-Irvine have created a three-dimensional, retina-like structure out of human embryonic stem cells that they hope could someday serve as a retinal transplant for people with macular degeneration and other diseases of the retina.

Their method, published recently in Journal of Neuroscience Methods, offers a potential new source of cells for retinal transplants. Specifically, the scientists created two types of cells from the human embryonic stem cells: early-stage retinal cells, and retinal pigment epithelium cells, which provide nourishment to the cells responsible for vision in the retina.

Robert Lanza, chief scientific officer at Advanced Cell Technologies, who was not involved in the study, says that his team discovered several years ago that, when turning human embryonic stem cells into RPE cells, other stem cells would spontaneously form layers, including patches of photoreceptors.

Reblog this post [with Zemanta]

Monday, May 17, 2010


A new technique, developed by scientists at ARC Vision Centre and Australian National University (ANU), can quantify damage caused by serious eye diseases.

Called multifocal pupillography, the method involves monitoring minute responses of the eye's pupil to light signals in different parts of the patient's visual field.

ARC Vision Centre and Australian National University (ANU) researchers led by Ted Maddess and Andrew James are pioneering this area of study for painless detection and monitoring of glaucoma, age-related macular degeneration (AMD) and diabetic retinopathy.

The technique relies on a feedback loop of nerve signals, which flow from each eye to the brain and back again to both pupils of the eyes by a secondary pathway, Maddess explains.

In our research we have been trying to localise the responses of the pupil to particular places across the visual field and hence, the eye's retina, said Maddes.

Reblog this post [with Zemanta]

Tuesday, April 27, 2010

Systems To Help Blind See Again



Venture Capital Dispatch blog of the Wall Street Journal reported that two companies are working on vision systems to help some blind people see again.

Second Sight Medical Products, Inc. based in Sylmar, Calif. is developing special eyeglasses that transmit pictures to a receiver embedded on the retina. The images are transferred by the optic nerve to the brain. The device is targeted to patients who have lost most of their vision as a result of retinal degeneration and whose nerve connections are still intact.

Israel's Nano Retina Inc. is also developing a similar device. The devices are priced from $50,000 to $100,000. Both companies are now working with insurance companies to have them pick up the costs for patients in need of such devices.

A third company, Optobionics Corp is pursuing a trickier and more costly approach: restoring function to the damaged retina by using the device to stimulate the rods and cones, rather than using the system as an adjunct to the retina. They are looking for funds to enter Phase III trials.

Reblog this post [with Zemanta]

Wednesday, October 28, 2009

MedPage Today reported that, according to a study presented at an ophthalmology meeting, "intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors can cause persistent hypertension in the eye after only one treatment," a complication affecting 3.45 percent of patients given bevacizumab (Avastin) or ranibizumab (Lucentis) for age-related macular degeneration (AMD).
After "retrospectively" looking at 116 wet AMD patients treated with either VEGF inhibitor at their tertiary referral center from 2006 through 2008, researchers found that four patients developed persistent ocular hypertension. However, the ocular hypertension usually responds to antiglaucoma medication, though it returns if the drops are discontinued, the investigators said.


Reblog this post [with Zemanta]

Monday, October 26, 2009


The New York Times that researchers from the Massachusetts Eye and Ear Infirmary, the VA Boston Healthcare System, and Cornell University have demonstrated retinal implants that they say will resist the jarring of daily use.

The implant contains a tiny array of electrodes whose tips slide into a snug berth just beneath the retina...and are held in place by natural suction. These electrodes prompt the remains of retinal circuits to transmit signals to the brain, allowing patients with retinitis pigmentosa, a disease that damages the rods and cones in the eye, and for macular degeneration, which also affects these photoreceptors, to detect light and dark and to find the edges of objects.
Reblog this post [with Zemanta]

Sunday, October 18, 2009

right_8108898277007Image by pmorgan via Flickr

Following a MedPage Today story, HealthDay reported that increased survival of extremely pre-term infants has led to a greater number of babies with vision problems caused by abnormal development of blood vessels in the retina, according to a study published in the Oct. issue of the Archives of Ophthalmology.

Swedish researchers examined data on 506 extremely pre-term infants (born before 27 weeks of gestation) who survived until their first eye examination and found that 368 (72.7 percent) had retinopathy of prematurity -- 37.9 percent with mild cases and 34.8 percent with severe cases. Notably, gestational age was a more significant risk factor for retinopathy of prematurity than birth weight.
Reblog this post [with Zemanta]

PHASE Ib CLINICAL TRIAL FOR AMD YIELDS PROMISING RESULTS.

OCT scan of a retina at 800nm with an axial re...Image via Wikipedia

MacuCLEAR, Inc. and Mystic Pharmaceuticals, Inc. have announced preliminary successful results of a Phase Ib Clinical Trial for the treatment and prevention of the progression of age-related macular degeneration (AMD). According to a press release from Mystic, the preliminary results indicated that MacuCLEAR's MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina. Trial participants used Mystic's VersiDoser ophthalmic delivery system to self-administer MC-1101 to the front of the eye during the trial. A key finding of the study was the successful migration of the drug to the back of the eye and the study included Proof of Concept (“POC”) indicators.


Reblog this post [with Zemanta]

Wednesday, October 07, 2009

Angiogenesis Inhibitor Works in Macular Edema



According to two studies presented at a retina meeting, patients with macular edema related to retinal vein occlusion had significant improvement in vision when treated with ranibizumab (Lucentis) in each of two dosages. In trials including approximately 400 patients apiece, researchers from Johns Hopkins University and Houston's Methodist Hospital randomized patients to monthly 0.5 mg or 0.3 mg intravitreal injections of ranibizumab, or to sham injections, for six months. Notably, 46 to 47 percent of patients in both ranibizumab groups improved by at least 15 letters, compared with 16.9 percent of the control group.
Reblog this post [with Zemanta]

Monday, October 05, 2009

Save your Vision Tips!

Young collard plants growing in a containerImage via Wikipedia


Eat Dark, Leafy Greens

Spinach, kale, collard greens, and other deep-colored vegetables contain lutein and zeaxanthin, two carotenoids that “have been associated with reducing the risk of developing cataracts and macular degeneration”. Try to eat two servings a day―for example, a handful of spinach in your salad at lunch and a side of broccoli at dinner.

Antioxidants

Foods such as berries, oranges, plums, and cherries help minimize free-radical damage, which is caused by environmental factors (like sunlight and pollution) and can quicken the hardening of lenses and contribute to cataracts and macular degeneration. Eat at least two servings a day―a cup of blueberries with your breakfast, say, and an orange as an afternoon snack.

Take a Multivitamin

A National Eye Institute study showed that supplements with antioxidant vitamins C and E, beta-carotene, and the minerals copper and zinc slowed the progression of advanced macular degeneration in high-risk patients. And a recent article in the Archives of Internal Medicine concluded that vitamins B6 and B12 and folic acid may also help. Still other studies suggest that vitamins may delay the onset of cataracts.


Get Your Omega-3s

You’ve heard that they’re good for your heart, but “evidence suggests omega-3 fatty acids found in certain fish, such as salmon, halibut, and tuna, can help maintain the eyes’ protective tear film, minimize dry eyes, and even prevent cataracts. Eat two to three servings a week, or consider taking a fish-oil supplement every day. Also cut down on red meat: A recent study showed that high consumption levels may increase the risk of macular degeneration.

Get some Veggie

These crisp vegetables, as well as other orange offerings, like pumpkin and butternut squash, contain beta-carotene, a carotenoid that may help keep eyes healthy.

Swear by Sunglasses

UV light is a major player in the hardening of the lenses and the development of cataracts and macular degeneration. That means it’s important to wear sunglasses with dark lenses that filter out 100 percent of UV rays (the label should indicate this) whenever you’re outside. we also recommend patients to put on a hat. “All glasses allow some light in through the tops and the sides” . “It bounces off your cheeks and right into your eyes.” Choose one that has a brim of at least four inches.

Reblog this post [with Zemanta]

Friday, October 02, 2009

Vision impacts life success


MedPage Today reported that, according to a study published online in Ophthalmology, patients with age-related macular degeneration (AMD) have a 50 percent increased risk of coronary heart disease.



Researchers from the Singapore National Eye Center conducted a population-based cohort study of 1,786 patients who didn't have heart disease and 2,228 patients without stroke at baseline. Patients were between the ages of 69 and 97. The investigators found that those with early macular degeneration had a higher cumulative incidence of heart disease than those without (25.8 percent versus 18.9 percent).

Notably, there was a significantly higher cumulative incidence of heart disease for those with specific signs of early macular degeneration -- soft drusen, hyperpigmentation, and RPE depigmentation

Reblog this post [with Zemanta]

Monday, September 28, 2009

Researchers advancing new ways of helping blind people see


On its front page, the New York Times reported that 38 patients from the US, Europe, and Mexico are beginning an intensive three-year research project involving electrodes surgically implanted in their eyes, a camera on the bridge of their noses, and a video processor strapped to their waists, in a burst of recent research aimed at one of science's most-sought-after holy grails: making the blind see.



Researchers involved in the project, the artificial retina, say they have plans to develop the technology to allow people to read, write and recognize faces. Meanwhile, other approaches to treating blindness include gene therapy, which has produced improved vision in people who are blind from one rare congenital disease. Stem cell research is considered promising, although far from producing results, and other studies involve a light-responding protein and retinal transplants.

Reblog this post [with Zemanta]

Saturday, August 01, 2009

Ozurdex Implant Approved for Macular Edema

OCT scan of a retina at 800nm with an axial re...Image via Wikipedia

An injectable eye implant approved by the U.S. Food and Drug Administration Thursday is the first product sanctioned to treat the eye disorder macular edema when it is caused by blockage of the retinal vein.

The Ozurdex eye implant treats macular edema by delivering a high concentration of the corticosteroid dexamethasone.

Macular edema occurs when the eye's macula -- a part of the retina -- swells because of fluid accumulation from leaking or blocked retinal veins. In a news release, device maker Allergan, Inc. said retinal vein occlusion is a significant cause of vision loss and the second most common disease of the retinal veins, behind diabetic retinopathy.

The implant, which is biodegradable, was evaluated in a pair of clinical studies involving about 1,300 people.

The treatment, to be injected in a physician's office, is expected to be available later this year

Reblog this post [with Zemanta]

Tuesday, July 07, 2009

Laser treatment may help reverse effects of dry AMD


A ground-breaking laser treatment may help reverse the effects of age-related macular degeneration (AMD). In early proof-of-concept trials involving about 50 people, the laser technique, which was developed by pioneering eye expert Professor John Marshall of King's College London, appeared to return the back of the eye to its youthful state.

In the technique, a painless 'short pulse' laser boosts the release of the enzymes to clean away natural waste materials, but without damaging the cells that enable vision. The researchers now plan further studies in patients already suffering from AMD in one eye with the aim of saving the sight in their better eye for as long as possible.

Professor Marshall said that he hoped the treatment would be available within two to five years. There is currently no treatment for the most common form of AMD -- known as 'dry' AMD -- which the new laser technique could prevent.

Reblog this post [with Zemanta]

Monday, July 06, 2009

Lucentis met late-stage trial goal in patients with macular edema due to BRVO

The same view with age-related macular degener...Image via Wikipedia

Genentech, Inc. announced that its macular degeneration drug Lucentis [ranibizumab] met its goal in a late stage trial, improving the vision of patients with macular edema due to branch retinal vein occlusion.

Currently, Lucentis is approved to treat neurovascular, or 'wet,' age-related macular degeneration. Genentech is now trying to get the drug approved for macular edema due to branch retinal vein occlusion, a condition in which the macula, or central part of the retina, swells because fluid leaks or builds up.
Reblog this post [with Zemanta]

Tuesday, June 30, 2009

Light-sensing worms provide a new tool for the study of vision

A team from the University in Michigan, led by Shawn Xu, has discovered that tiny worms can sense light.

They discovered that the chemical reactions used by the C. elegans ( a 1mm sized worm which is one of the most commonly used model animals in genetic research) are rather similar to the ones in humans. This discovery means that from now on the worm can be used for the research of building blocks of human vision, as well as how disrupting the phototransduction pathway can lead to eye disease.

This discovery may lead to further breakthroughs in the research of vision, helping researchers understand the basis of human vision diseases and promote the understanding of the evolutionary development of eyes in various species.

Reblog this post [with Zemanta]

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review